Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | TACR3 | P29371 | 9/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354537 | 0.91 | MEN1 (0.37) | SLC6A9TACR3RAB9AKMT2ATRPV1 | |
| SCHEMBL4357027 | 0.88 | TACR3 (0.46) | TACR3KMT2ASLC2A1 | |
| SCHEMBL4361680 | 0.87 | TACR3 (0.45) | TACR3KMT2ASLC2A1 | |
| SCHEMBL8263391 | 0.85 | GAA (0.49) | SLC6A9TACR3GAASLC2A1 | |
| SCHEMBL4359090 | 0.82 | KMT2A (0.40) | SLC6A9TACR3KMT2AGAASLC2A1 | |
| SCHEMBL4351001 | 0.81 | TACR3 (0.38) | SLC6A9TACR3KMT2AGAASLC2A1 | |
| SCHEMBL4358870 | 0.79 | TACR3 (0.43) | TACR3LMNASLC2A1 | |
| SCHEMBL4363718 | 0.79 | TACR3 (0.43) | TACR3SLC2A1 | |
| SCHEMBL4356096 | 0.79 | KDM4E (0.41) | SLC6A9TACR3RAB9A | |
| SCHEMBL4355261 | 0.77 | CXCR5 (0.44) | SLC6A9TACR3LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | PNMT, SLC18A2, COMT | SLC6A9 1038/4885TACR3 2005/4885LMNA 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.